Lumrotatug

罗美妥塔单抗

Report date: 2026/05/25 20:02:40

Base Information

Drug NameLumrotatug
Drug Alias NameCM-313
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAnti-CD38
TargetsLymphocyte differentiation antigen CD38
Therapy Area/IndicationsLupus Erythematosus, SystemicThrombocytopeniaBlood Platelet Disorders +[10
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesKeymed Biosciences Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Inactive CompaniesN/A
Active IndicationsLupus Erythematosus, SystemicThrombocytopeniaBlood Platelet Disorders +[10
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A